circle

INVESTORS & MEDIA

INVESTOR OVERVIEW

  • Webcast
    X 40th Annual J.P. Morgan Healthcare Conference
    Jan 11, 2022 4:30 PM EST

    40th Annual J.P. Morgan Healthcare Conference
    Jan 11, 2022 4:30 PM EST
  • Webcast
    X Cytokinetics and Royalty Pharma Announce Funding Agreements Totaling up to $450 Million
    Jan 7, 2022 8:30 AM EST

    Cytokinetics and Royalty Pharma Announce Funding Agreements Totaling up to $450 Million
    Jan 7, 2022 8:30 AM EST

Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. As a leader in muscle biology and the mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to impact muscle function and contractility.

ANNUAL REPORT

CORPORATE PRESENTATION

CYTOKINETICS FACT SHEETS

fact1

Company

09/21/18
( FY )
ALS

ALS

03/11/18
( FY )
SMA

SMA

07/13/18
( FY )

NEWS

Date Title and Summary
Toggle Summary Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif. , Jan. 10, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on December 31, 2021 it granted stock options to purchase an aggregate of 90,000 shares of common stock to 9 new employees, whose employment commenced in December 2021 , as
Toggle Summary Cytokinetics and Royalty Pharma Announce Funding Agreements Totaling up to $450 Million
Royalty Pharma Extends Capital to Cytokinetics to Support the Commercial Launch of Omecamtiv Mecarbil and the Further Development of Aficamten Royalty Pharma Purchases Royalties on Future Sales of Aficamten Cytokinetics to Host Conference Call and Webcast Today at 8:30 am Eastern Time SOUTH SAN
Toggle Summary Cytokinetics to Participate in the 40th Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif. , Jan. 03, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum , President and Chief Executive Officer, is scheduled to present virtually at the 40 th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022
Toggle Summary Cytokinetics and JI XING Announce Expansion of Collaboration to Include Licensing of Omecamtiv Mecarbil in China; RTW to Add to Its Investment in Cytokinetics
JI XING to Develop and Commercialize Novel Cardiac Myosin Activator in Patients with Heart Failure Cytokinetics to Receive $70 Million in Committed Capital ; Up to an Additional $330 Million in Potential Milestone Payments Plus Royalties Cytokinetics to Host Conference Call and Webcast Today at

EVENTS

There are currently no events to display.